Scholarlink

Background <p>Adjuvant chemotherapy (ACT) is the standard of care after resection for pancreatic ductal adenocarcinoma (PDAC); however, not all patients may derive equal benefit. This study explored morphological parameters to help tailor ACT indications.</p> Methods <p>This retrospective study included patients who underwent upfront resection for PDAC between 2013 and 2019 at two tertiary centers. Independent prognostic factors were identified using multivariable Cox regression. Optimal cut-offs were determined via maximally selected log-rank statistics. The impact of ACT on overall survival (OS) was evaluated in subgroups stratified by prognostic determinants.</p> Results <p>Among 326 included patients, 62.3% received ACT. Independent OS predictors included resection margin status (HR = 4.89, <i>p</i> &lt; 0.001), lymph node ratio (LNR) (HR = 20.6, <i>p</i> &lt; 0.001), tumor grade, multivisceral resection, and ACT. Notably, in a specific subgroup combining R0 resection with highly favorable nodal parameters (N0 with ≥ 19 examined lymph nodes, or N+ with LNR ≤ 0.0833), ACT did not significantly improve OS (HR = 0.78, <i>p</i> = 0.296).</p> Conclusions <p>These hypothesis-generating findings suggest that precise morphology-based risk stratification might identify a PDAC subpopulation deriving limited benefit from ACT. While rigorous prospective validation is required, these criteria offer a framework for future trials exploring personalized, de-escalated systemic therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tailoring Adjuvant Chemotherapy After Pancreatic Cancer Resection Using Morphology-Based Risk Stratification

  • 期刊论文

  • 发表日期：

    2026年5月22日

查看全文
  • Andrej Nikov,
  • Tereza Husárová,
  • Martin Oliverius,
  • Tomáš Sychra,
  • Zdeněk Šubrt

摘要

Background

Adjuvant chemotherapy (ACT) is the standard of care after resection for pancreatic ductal adenocarcinoma (PDAC); however, not all patients may derive equal benefit. This study explored morphological parameters to help tailor ACT indications.

Methods

This retrospective study included patients who underwent upfront resection for PDAC between 2013 and 2019 at two tertiary centers. Independent prognostic factors were identified using multivariable Cox regression. Optimal cut-offs were determined via maximally selected log-rank statistics. The impact of ACT on overall survival (OS) was evaluated in subgroups stratified by prognostic determinants.

Results

Among 326 included patients, 62.3% received ACT. Independent OS predictors included resection margin status (HR = 4.89, p < 0.001), lymph node ratio (LNR) (HR = 20.6, p < 0.001), tumor grade, multivisceral resection, and ACT. Notably, in a specific subgroup combining R0 resection with highly favorable nodal parameters (N0 with ≥ 19 examined lymph nodes, or N+ with LNR ≤ 0.0833), ACT did not significantly improve OS (HR = 0.78, p = 0.296).

Conclusions

These hypothesis-generating findings suggest that precise morphology-based risk stratification might identify a PDAC subpopulation deriving limited benefit from ACT. While rigorous prospective validation is required, these criteria offer a framework for future trials exploring personalized, de-escalated systemic therapy.